{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T05:57:09Z","timestamp":1673589429514},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","respiratoryinvestigation.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.resinv.2016.12.002","type":"journal-article","created":{"date-parts":[[2017,1,12]],"date-time":"2017-01-12T15:54:17Z","timestamp":1484236457000},"page":"181-183","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"55","author":[{"given":"Hiroaki","family":"Ogata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isamu","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goichi","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teppei","family":"Obara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayo","family":"Ijichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Iwama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taishi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2016.12.002_bib1","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.4143\/crt.2012.44.1.63","article-title":"Five cases report of solid tumor synchronously with hematologic malignancy","volume":"44","author":"Cui","year":"2012","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.resinv.2016.12.002_bib2","series-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.resinv.2016.12.002_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001\u20132004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.resinv.2016.12.002_bib4","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ajh.23203","article-title":"Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management","volume":"87","author":"Parikh","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.resinv.2016.12.002_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ajh.2830190214","article-title":"Pancytopenia with a hypercellular bone marrow as a possible paraneoplastic syndrome","volume":"19","author":"Haznedar","year":"1985","journal-title":"Am J Hematol"},{"key":"10.1016\/j.resinv.2016.12.002_bib6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ajh.2830160411","article-title":"Pancytopenia with hypercellular bone marrow\u2014a possible paraneoplastic syndrome in carcinoma of the lung: a report of three cases","volume":"16","author":"Raz","year":"1984","journal-title":"Am J Hematol"},{"key":"10.1016\/j.resinv.2016.12.002_bib7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/ajh.2830220116","article-title":"Association of chronic myelomonocytic leukemia and carcinoma: a possible paraneoplastic myelodysplasia","volume":"22","author":"Sans-Sabrafen","year":"1986","journal-title":"Am J Hematol"},{"key":"10.1016\/j.resinv.2016.12.002_bib8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/bjc.1987.154","article-title":"Prognostic factors and survival in chronic myelomonocytic leukaemia (CMML)","volume":"56","author":"Stark","year":"1987","journal-title":"Br J Cancer"},{"key":"10.1016\/j.resinv.2016.12.002_bib9","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2016.12.002_bib10","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2016.12.002_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resinv.2016.12.002_bib12","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resinv.2016.12.002_bib13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resinv.2016.12.002_bib14","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature08240","article-title":"Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms","volume":"460","author":"Sanada","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.resinv.2016.12.002_bib15","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.clml.2015.06.002","article-title":"Patients with therapy-related CMML have shorter median overall survival than those with de novo CMML: Mayo Clinic long-term follow-up experience","volume":"15","author":"Subari","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.resinv.2016.12.002_bib16","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1182\/blood-2008-09-038935","article-title":"How I treat patients with myelodysplastic syndromes","volume":"113","author":"Stone","year":"2009","journal-title":"Blood"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534516302040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534516302040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T03:58:17Z","timestamp":1536119897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534516302040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S2212534516302040"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2016.12.002","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2016.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}